Clinical trial
Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive…
NCT00251693 · Takeda, Industry · Completed
Key facts
| NCT number | NCT00251693 |
|---|---|
| Title | Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis |
| Official title | A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg Once- Daily [QD] and 90 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis |
| Lead sponsor | Takeda, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Esophagitis, Reflux, Peptic |
| Intervention type | Drug |
| Interventions | Dexlansoprazole MR, Lansoprazole |
| Enrollment | 2,038 |
| Start date | Dec 1, 2005 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | Nov 10, 2005 |
| Last update posted | Feb 3, 2012 |
| Countries | Australia, Bulgaria, Canada, Czechia, Germany, Hungary, India, Latvia, Lithuania, New Zealand, Peru, Poland and 3 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: